SCHEMBL15280878

SCHEMBL15280878

CC(C)(C)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](O)C1OP(=O)(O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 4/20 0.60
P2RY1 P47900 4/20 0.59
P2RY2 P41231 4/20 0.59
ADORA1 P30542 2/20 0.59
SRC P12931 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
P2RX1 P51575 1/20 0.59
P2RX3 P56373 1/20 0.59
P2RX4 Q99571 1/20 0.59
P2RX2 Q9UBL9 1/20 0.59
ALDH1A1 P00352 1/20 0.59
DNPH1 O43598 1/20 0.58
PRKAB2 O43741 1/20 0.58
TRPM2 O94759 1/20 0.58
LDHA P00338 1/20 0.58
ADRB2 P07550 1/20 0.58
FBP1 P09467 1/20 0.58
PRKAG1 P54619 1/20 0.58
PRKAA2 P54646 1/20 0.58
PDE4D Q08499 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19887071 1.00 RNASEL (0.60) RNASELP2RY1P2RY2ADORA1SRC
SCHEMBL22292292 1.00 RNASEL (0.60) RNASELP2RY1P2RY2ADORA1SRC
SCHEMBL19887061 0.92 ADORA1 (0.55) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL22292289 0.92 ADORA1 (0.55) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL15280834 0.92 ADORA1 (0.55) P2RY1P2RY2ADORA1SRCSMN1; SMN2
SCHEMBL22060530 0.91 ADORA1 (0.55) RNASELP2RY1ADORA1
SCHEMBL15280855 0.91 ADORA1 (0.55) RNASELP2RY1ADORA1
SCHEMBL15280847 0.91 ADORA1 (0.55) RNASELP2RY1ADORA1
SCHEMBL19522843 0.90 RNASEL (0.64) RNASELP2RY1P2RY2ADORA1SRC
SCHEMBL8281683 0.90 RNASEL (0.61) RNASELP2RY1P2RY2ADORA1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
US-8987226-B2 Modified single-stranded polynucleotides DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-24 US disclosed
US-20130253038-A1 Modified Single-Stranded Polynucleotide DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC RNASEL 413/4885P2RY1 1522/4885P2RY2 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.